0
Bevacizumab is a humanized monoclonal antibody (mAb) targeting vascular endothelial growth factor (VEGF), which causes excessive growth of new blood vessels from pre-existing ones in the form of an...
More >- INICIO
-
Genéricos
Novedades
- Pfizer producirá la píldora genérica de COVID-19 en ocho países de América Latina
- First eslicarbazepine epilepsy generic to be approved in China
- Pfizer and Merck COVID-19 antiviral progress
- Sun Pharma and Dr Reddy’s generics progress in EU and US
Investigación
- Call for drug pricing transparency
- High price of cancer medicines make treatment unaffordable globally
- US brand-name drug market exclusivity periods remain relatively unchanged over the past decade
- Consideraciones para la evaluación de DIU genéricos que contienen levonorgestrel
-
Biosimilares
Novedades
- Canada approves adalimumab biosimilars Simlandi and Yuflyma
- Canada approves filgrastim biosimilar Nypozi
- Etanercept biosimilars delayed until 2029 in US
- New Zealand announces funding for adalimumab biosimilar
Investigación
- Biological standardization of bevacizumab: impact on global harmonization of potency assessment
- Real-world data cannot replace post-approval confirmatory trials
- Diferencias en estudios clínicos y farmacovigilancia de medicamentos biológicos en América Latina
- Biosimilar uptake and the education of healthcare provider
- MORE EDITORIAL SECTIONS
- Search
